Uniqure N.V. annual report, FY2023

uniQure N.V. — FY2023 Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2023; filed February 28, 2024. This is an annual report, not a standalone Q4 report. Amounts are in U.S. dollars unless stated otherwise.

Business context

uniQure is a gene-therapy company developing treatments for rare and serious diseases. HEMGENIX, its hemophilia B gene therapy, is approved in the U.S. and EU and commercialized by CSL Behring; uniQure manufactures product and receives royalties and certain milestone payments. Its lead investigational program is AMT-130 for Huntington’s disease, alongside clinical-stage programs for SOD1-ALS, refractory mesial temporal lobe epilepsy (MTLE), and Fabry disease.

Financial performance and liquidity

Metric	FY2023	FY2022
Total revenue	$15.8 million	$106.5 million
Research and development expense	$214.9 million	$197.6 million
Selling, general and administrative expense	$74.6 million	$55.1 million
Net loss	$308.5 million	$126.8 million
Net loss per share, basic and diluted	$6.47	$2.71
Net cash used in operating activities	$145.9 million	$145.1 million

• Revenue declined about 85% year over year. FY2023 included $2.8 million of HEMGENIX royalties, $10.8 million of contract manufacturing revenue, and $2.3 million of collaboration revenue. FY2022 included a $100 million HEMGENIX first-sale milestone; FY2021 revenue was elevated by CSL Behring upfront and milestone payments.
• Operating expenses were $303.1 million, up from $256.0 million. Manufacturing costs were $13.6 million against $10.8 million of contract manufacturing revenue; costs included a $1.6 million inventory write-down.
• Cash, cash equivalents and investment securities totaled $617.9 million at year-end; including restricted cash, cash and investments were $621.1 million. Cash and cash equivalents alone were $241.4 million, and current investment securities were $376.5 million.
• Operating cash use was broadly flat year over year. Investing activities used $205.7 million, including purchases and maturities of government securities; financing activities provided $362.7 million, mainly from royalty financing.
• Debt included $100 million principal owed under the Hercules facility, due January 2027, and a $394.2 million royalty-financing liability. Hercules debt carried a 13.2% interest rate at year-end. The filing reports $47.6 million of future Hercules interest and financing fees, in addition to principal repayment.
• Year-end total assets were $831.7 million, total liabilities $624.0 million, and shareholders’ equity $207.7 million. The filing reports no operating margin; the company recorded a substantial operating loss.

Material changes versus prior period

• Net loss widened to $308.5 million from $126.8 million, reflecting lower revenue, increased R&D and SG&A, higher interest expense, and foreign-exchange results that shifted from a $23.2 million gain in 2022 to a $1.7 million loss in 2023.
• R&D expense increased 9% and SG&A increased 35%. uniQure attributed higher costs to personnel, facilities, clinical and manufacturing activity, and a $15.9 million fair-value charge on contingent consideration related to uniQure France.
• In May 2023, uniQure received $375 million upfront for selling a portion of future HEMGENIX royalties. Net proceeds after transaction costs were $370.1 million. The arrangement is accounted for as debt; $26.9 million of interest expense was recorded in 2023. The purchaser is generally entitled to 1.85 times the upfront payment by June 2032, or up to 2.25 times through 2038 if the earlier cap is not met.
• In October 2023, the company announced and completed a reorganization: it discontinued investments in more than half of its research programs, eliminated approximately 20% of its workforce, closed its Lexington research laboratory, and consolidated manufacturing and development activities. Recorded restructuring costs were approximately $4.0 million, including $2.5 million in severance and $1.4 million in impairment charges.
• The BMS collaboration terminated in February 2023; uniQure recorded no BMS collaboration revenue in 2023.

Outlook, commentary and key risks

• Management expects year-end cash and investment resources to fund operations into the second quarter of 2027 under its current plan. This estimate is assumption-dependent; management expects additional funding would be needed to advance AMT-130 or other candidates into late-stage development.
• Management expects R&D expenses to decline after the reorganization, until a candidate is advanced into late-stage clinical development. No product-sales or profitability guidance is provided in the supplied filing text.
• AMT-130 interim data through 30 months showed generally manageable tolerability and exploratory signals of preserved function versus baseline and a non-concurrent natural-history cohort. Four AMT-130-related serious adverse events in the high-dose cohort involved CNS inflammation or severe headache; patients improved with glucocorticoids. These are early, interim findings, and the company cautions that biomarkers and natural-history comparisons are not validated substitutes for controlled efficacy evidence.
• AMT-260 and AMT-191 received FDA IND clearance in 2023; AMT-162 was licensed from Apic Bio. Clinical results, regulatory agreement on trial designs, enrollment, manufacturing execution, and gene-therapy safety remain significant uncertainties.
• Contingent milestone obligations to uniQure France’s former shareholders include up to €30 million associated with initial AMT-260 clinical dosing and up to €160 million tied to later development and approvals. The recorded contingent-consideration liability was $43.0 million at year-end; future payments and timing depend on milestones.
• Other principal risks include continued operating losses and need for capital, Hercules covenants and collateral over substantially all assets, HEMGENIX manufacturing transfer to a CSL-designated third party, intellectual-property challenges, competition, reimbursement and pricing uncertainty, and potential clinical or regulatory setbacks. The company reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions and reported no critical audit matters.

Important facts for investors to verify

• Latest AMT-130 trial data, including patient follow-up, safety, efficacy endpoints, and regulatory feedback on the development path.
• HEMGENIX commercial sales, royalties retained after the royalty sale, any 2024 sales-linked milestone, and the royalty purchaser’s repayment progress and caps.
• Cash runway assumptions, quarterly operating cash use, and financing needed for late-stage trials.
• Hercules facility covenants, 2027 maturity and repayment/refinancing plans; also verify the accounting and cash-flow implications of the royalty-financing liability.
• AMT-260 milestone-payment timing and valuation, and clinical progress for AMT-162 and AMT-191.
• Whether the reorganization produces sustained cost savings without delaying prioritized programs, and the timing and economics of CSL Behring’s planned HEMGENIX manufacturing transfer.